Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PhaseBio Pharmaceuticals, Inc. - Common Stock (NQ: PHAS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PhaseBio Pharmaceuticals, Inc. - Common Stock

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Provides Pemziviptadil (PB1046) Program Update
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Appoints William D. Humphries to Board of Directors
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.